Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

Summary.  The aim of this work was to estimate the future disease burden of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections in the United States until the year 2030. Two back‐calculation models of the HIV and the HCV epidemic were developed. They were based on US epidemiological data regarding prevalence, age and gender of incident cases, AIDS, hepatocellular carcinoma (HCC) mortality and general population mortality from the Centers for Disease Control and WHO. Based on the HCV back‐calculation model, HCV incidence peaked in 1984 at 350 000 new infections and then fell to about 77 000 in 1998. Based on the HIV back‐calculation model, HIV incidence reached its maximum in 1989 at 142 000 new infections and then declined to 79 000 in 1998. Mortality related to HCV (death from liver failure or HCC) rose from about 3700 in 1998 and is expected to peak at about 13 000 in 2030. Predicted HCV mortality would fall only if increased access to or more effective antiviral therapy occurs. For comparison, observed HIV‐related mortality was 14 400 in 1998 and projected to be 4200 for 2030. With the availability of effective highly active antiretroviral therapy for HIV infection, mortality from HIV appears to have declined substantially, whereas HCV‐related deaths as a result of pre‐1999 infections will likely continue to increase over the next 25 years.

[1]  J. Ward,et al.  The completeness, validity, and timeliness of AIDS surveillance data. , 2001, Annals of epidemiology.

[2]  J. Goedert,et al.  Backcalculation of the number with human immunodeficiency virus infection in the United States. , 1991, American journal of epidemiology.

[3]  R. Brookmeyer,et al.  The Minimum Size of the AIDS Epidemic in the United States , 1986 .

[4]  J. Kaldor,et al.  Modelling the hepatitis C virus epidemic in Australia. , 2007, Drug and alcohol dependence.

[5]  F. Carrat,et al.  Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. , 2006, Journal of hepatology.

[6]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[7]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[8]  S Chevret,et al.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death , 2000, Gut.

[9]  D. Marquardt.  An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[10]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[11]  G. Davis,et al.  Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  M Gwinn,et al.  Prevalence of HIV infection in the United States, 1984 to 1992. , 1996, JAMA.

[13]  W. Kim,et al.  The burden of hepatitis C in the United States , 2002, Hepatology.

[14]  J. Thornton,et al.  Prevalence of HIV infection , 1995, BMJ.

[15]  J. Buehler,et al.  The completeness of AIDS case reporting, 1988: a multisite collaborative surveillance project. , 1992, American journal of public health.

[16]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[17]  A Muñoz,et al.  Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. , 2001, American journal of epidemiology.

[18]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[19]  R Brookmeyer,et al.  Reconstruction and future trends of the AIDS epidemic in the United States. , 1991, Science.

[20]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[21]  Manal M. Hassan,et al.  Rising Prevalence of Hepatitis C Virus Infection Among Patients Recently Diagnosed With Hepatocellular Carcinoma in the United States , 2002, Journal of Clinical Gastroenterology.

[22]  M. Segal,et al.  Different AIDS incubation periods and their impacts on reconstructing human immunodeficiency virus epidemics and projecting AIDS incidence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[24]  D. Costagliola,et al.  Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. , 2002, Journal of acquired immune deficiency syndromes.

[25]  R. Carroll,et al.  Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. , 1992, Statistics in medicine.

[26]  H. El‐Serag,et al.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States , 2001, Hepatology.

[27]  M. Mizokami,et al.  Molecular evolutionary analysis predicts the incidence of hepatocellular carcinoma in the United States and Japan , 2004, Cancer Chemotherapy and Pharmacology.

[28]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[29]  Ron Brookmeyer,et al.  MINIMUM SIZE OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) EPIDEMIC IN THE UNITED STATES , 1986, The Lancet.

[30]  E. A. Robinson.  Hepatitis C in asymptomatic blood donors , 1995, BMJ.

[31]  H. Margolis,et al.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. , 1990, JAMA.

[32]  Milton C Weinstein,et al.  Empirically calibrated model of hepatitis C virus infection in the United States. , 2002, American journal of epidemiology.

[33]  S. Zou,et al.  Prediction of hepatitis C burden in Canada. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[34]  K. McGlynn,et al.  Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. , 2004, Gastroenterology.

[35]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[36]  Ian C. Marschner,et al.  A method for estimating the age-specific relative risk of HIV infection from AIDS incidence data , 1993 .

[37]  B. Efron,et al.  A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .

[38]  T. Gojobori,et al.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[40]  John B Wong,et al.  Comparing the public health burden of chronic hepatitis C and HIV infection in France. , 2004, Journal of hepatology.

[41]  J. Buehler,et al.  The Completeness of AIDS Surveillance , 1992, Journal of acquired immune deficiency syndromes.

[42]  A. Valleron,et al.  Modeling the hepatitis C virus epidemic in france , 1999, Hepatology.

[43]  P. Rosenberg,et al.  Trends in HIV incidence among young adults in the United States. , 1998, JAMA.